Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Vaxxinity Gets Fast Track designation from FDA For Alzheimer's disease Candidate UB-311

Vaxxinity, Inc. (NASDAQ: VAXX) announced that UB-311 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

urban-gro Closes Acquisition Of Emerald Construction Management

urban-gro Closes Acquisition Of Emerald Construction Management

urban-gro (NASDAQ: UGRO) completed its acquisition of Emerald Construction Management Inc.

What's Going On With Redbox Stock Today?

What's Going On With Redbox Stock Today?

Redbox Entertainment Inc (NASDAQ: RDBX) shares are trading higher on above-average volume Monday amid increased retail investor interest.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

springbig And Tuatara Capital Amend Merger Terms, Here Are The Details

SpringBig, Inc. and Tuatara Capital Acquisition Corporation (NASDAQ: TCAC) announced amendments to their merger agreement and securing of additional committed capital to ensure the business combination has adequate funding to execute its growth plan.

AFC Gamma Enters Into $60M Senior Secured Revolving Credit Facility With Commitments From Two FDIC-Insured Banks

AFC Gamma, Inc. (NASDAQ: AFCG) has entered into a senior secured revolving credit facility with $60 million of current commitments from two FDIC-insured banks and the ability to increase the facility to $100 million.

FDA Issues Complete Response Letter (CRL) to Axsome Therapeutics for AXS-07 In Acute Migraine

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Axsome Therapeutics, Inc. (NASDAQ: AXSM) regarding its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.

Mid-Morning Market Update: Markets Mostly Lower; US Factory Growth Slows In April

U.S. stocks traded mostly lower this morning, with the Dow Jones tumbling around 100 points on Monday.

inkl

Read news from The Economist, FT, and more,
with one subscription

Earnings Preview: Blueprint Medicines

Earnings Preview: Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Blueprint Medicines will report an earnings per share (EPS) of $-1.94.

Expert Ratings for eBay

Expert Ratings for eBay

Within the last quarter, eBay (NASDAQ:EBAY) has observed the following analyst ratings:

What Are Whales Doing With Meta Platforms

What Are Whales Doing With Meta Platforms

Someone with a lot of money to spend has taken a bullish stance on Meta Platforms (NASDAQ:FB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Earnings Outlook For Paramount Global

Earnings Outlook For Paramount Global

Paramount Global (NASDAQ:PARA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Paramount Global will report an earnings per share (EPS) of $0.51.

Analyst Ratings for Host Hotels & Resorts

Analyst Ratings for Host Hotels & Resorts

Within the last quarter, Host Hotels & Resorts (NASDAQ:HST) has observed the following analyst ratings:

Earnings Preview For Biogen

Earnings Preview For Biogen

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an earnings per share (EPS) of $4.38.

$100 Invested In Activision Blizzard 15 Years Ago Would Be Worth This Much

$100 Invested In Activision Blizzard 15 Years Ago Would Be Worth This Much

Activision Blizzard (NASDAQ:ATVI) has outperformed the market over the past 15 years by 7.67% on an annualized basis producing an average annual return of 14.6%. Currently, Activision Blizzard has a market capitalization of $60.70 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022

Expert Ratings for Baidu

Over the past 3 months, 4 analysts have published their opinion on Baidu (NASDAQ:BIDU) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

What's Going On With Amazon Shares?

Amazon.com, Inc. (NASDAQ: AMZN) shares are trading lower by 4.17% at $2,381.75. The move appears to be on continued weakness after the company last week reported first-quarter earnings results and issued second-quarter sales guidance below analyst estimates.

Amazon.com Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Amazon.com (NASDAQ:AMZN) reported Q1 sales of $116.44 billion. Earnings fell to a loss of $3.84 billion, resulting in a 126.84% decrease from last quarter.

Get all your
news in one place.

100's of premium titles.
One news app.

Apple's Return on Invested Capital Overview

Pulled from Benzinga Pro data, Apple (NASDAQ:AAPL) posted Q2 earnings of $25.01 billion, an increase from Q1 of 27.78%. Sales dropped to $97.28 billion, a 21.52% decrease between quarters.

Hertz Global Holdings Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Hertz Global Holdings (NASDAQ:HTZ) earned $426.00 million, a 262.6% increase from the preceding quarter. Hertz Global Holdings's sales decreased to $1.81 billion, a 7.13% change since Q4.

Looking Into Solid Biosciences's Return On Capital Employed

Solid Biosciences (NASDAQ:SLDB) brought in sales totaling $1.93 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 36.1%, resulting in a loss of $25.33 million.

Faro Technologies's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q1, Faro Technologies's (NASDAQ:FARO) reported sales totaled $76.66 million. Despite a 69.45% increase in earnings, the company posted a loss of $9.69 million.

Repligen's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, Repligen (NASDAQ:RGEN) earned $46.96 million, a 61.33% increase from the preceding quarter. Repligen also posted a total of $206.40 million in sales, a 10.66% increase since Q4.

Looking Into Surmodics's Return On Capital Employed

Surmodics (NASDAQ:SRDX) brought in sales totaling $26.11 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 45.2%, resulting in a loss of $4.08 million.

Coherus and Junshi Biosciences Receive CRL from FDA for Toripalimab in combination with Gemcitabine and Cisplatin In metastatic nasopharyngeal carcinoma (NPC)

Shanghai Junshi Biosciences and Coherus BioSciences, Inc. (NASDAQ: CHRS) received a complete response letter (CRL) from the U.S.

1 … 603 604 605 606

Organisations

Activision Blizzard

Paramount Global

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

365,576 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play